FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151146130> ?p ?o ?g. }

• W2151146130 endingPage "519" @default.
• W2151146130 startingPage "513" @default.
• W2151146130 abstract "Background & AimsTopical 5-aminosalicylates (5-ASAs) such as mesalamine are effective in inducing remission in patients with mild to moderately active ulcerative colitis (UC). However, there has been no meta-analysis of their efficacy in preventing relapse of quiescent UC.MethodsWe searched MEDLINE, EMBASE, and the Cochrane central register of controlled trials through July 2011 for randomized controlled trials comparing the effects of topical 5-ASAs with placebo in adults with quiescent UC. Dichotomous data were pooled to obtain relative risk (RR) of relapse of disease activity. The number needed to treat (NNT) was calculated from the reciprocal of the risk difference. Adverse events data were summarized.ResultsThe search identified 3061 citations; we analyzed data from seven (555 patients). All trials used mesalamine, but only one included patients with extensive disease. The duration of therapy ranged from 6–24 months. The RR of relapse of disease activity in patients with quiescent UC who were given topical mesalamine, compared with placebo, was 0.60 (95% confidence interval, 0.49–0.73; NNT = 3); there was no significant heterogeneity between studies (I2 = 21%, P = .27). No significant differences in rates of adverse events rates were detected (RR = 1.01; 95% confidence interval, 0.59–1.72).ConclusionsOn the basis of a meta-analysis of 7 randomized controlled trials, topical mesalamine is effective in preventing relapse of quiescent UC, with no greater number of adverse events than placebo. However, because most studies included only patients with left-sided disease or proctitis, the efficacy of topical mesalamine in preventing relapse in patients with more extensive quiescent UC is not known. Topical 5-aminosalicylates (5-ASAs) such as mesalamine are effective in inducing remission in patients with mild to moderately active ulcerative colitis (UC). However, there has been no meta-analysis of their efficacy in preventing relapse of quiescent UC. We searched MEDLINE, EMBASE, and the Cochrane central register of controlled trials through July 2011 for randomized controlled trials comparing the effects of topical 5-ASAs with placebo in adults with quiescent UC. Dichotomous data were pooled to obtain relative risk (RR) of relapse of disease activity. The number needed to treat (NNT) was calculated from the reciprocal of the risk difference. Adverse events data were summarized. The search identified 3061 citations; we analyzed data from seven (555 patients). All trials used mesalamine, but only one included patients with extensive disease. The duration of therapy ranged from 6–24 months. The RR of relapse of disease activity in patients with quiescent UC who were given topical mesalamine, compared with placebo, was 0.60 (95% confidence interval, 0.49–0.73; NNT = 3); there was no significant heterogeneity between studies (I2 = 21%, P = .27). No significant differences in rates of adverse events rates were detected (RR = 1.01; 95% confidence interval, 0.59–1.72). On the basis of a meta-analysis of 7 randomized controlled trials, topical mesalamine is effective in preventing relapse of quiescent UC, with no greater number of adverse events than placebo. However, because most studies included only patients with left-sided disease or proctitis, the efficacy of topical mesalamine in preventing relapse in patients with more extensive quiescent UC is not known." @default.
• W2151146130 created "2016-06-24" @default.
• W2151146130 creator A5011739304 @default.
• W2151146130 creator A5026025919 @default.
• W2151146130 creator A5044392782 @default.
• W2151146130 creator A5056355381 @default.
• W2151146130 creator A5083726032 @default.
• W2151146130 date "2012-05-01" @default.
• W2151146130 modified "2023-10-18" @default.
• W2151146130 title "Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis" @default.
• W2151146130 cites W1835567156 @default.
• W2151146130 cites W1984426896 @default.
• W2151146130 cites W2005333320 @default.
• W2151146130 cites W2045578045 @default.
• W2151146130 cites W2053395478 @default.
• W2151146130 cites W2054044633 @default.
• W2151146130 cites W2055879151 @default.
• W2151146130 cites W2071748269 @default.
• W2151146130 cites W2078905380 @default.
• W2151146130 cites W2082034492 @default.
• W2151146130 cites W2083759302 @default.
• W2151146130 cites W2097388657 @default.
• W2151146130 cites W2101604689 @default.
• W2151146130 cites W2107328434 @default.
• W2151146130 cites W2116569898 @default.
• W2151146130 cites W2119605658 @default.
• W2151146130 cites W2125435699 @default.
• W2151146130 cites W2138119117 @default.
• W2151146130 cites W2156250460 @default.
• W2151146130 cites W2157823046 @default.
• W2151146130 cites W2418815041 @default.
• W2151146130 cites W2614583537 @default.
• W2151146130 cites W4295333203 @default.
• W2151146130 doi "https://doi.org/10.1016/j.cgh.2011.10.043" @default.
• W2151146130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22083024" @default.
• W2151146130 hasPublicationYear "2012" @default.
• W2151146130 type Work @default.
• W2151146130 sameAs 2151146130 @default.
• W2151146130 citedByCount "45" @default.
• W2151146130 countsByYear W21511461302012 @default.
• W2151146130 countsByYear W21511461302013 @default.
• W2151146130 countsByYear W21511461302014 @default.
• W2151146130 countsByYear W21511461302015 @default.
• W2151146130 countsByYear W21511461302016 @default.
• W2151146130 countsByYear W21511461302017 @default.
• W2151146130 countsByYear W21511461302018 @default.
• W2151146130 countsByYear W21511461302019 @default.
• W2151146130 countsByYear W21511461302020 @default.
• W2151146130 countsByYear W21511461302021 @default.
• W2151146130 countsByYear W21511461302023 @default.
• W2151146130 crossrefType "journal-article" @default.
• W2151146130 hasAuthorship W2151146130A5011739304 @default.
• W2151146130 hasAuthorship W2151146130A5026025919 @default.
• W2151146130 hasAuthorship W2151146130A5044392782 @default.
• W2151146130 hasAuthorship W2151146130A5056355381 @default.
• W2151146130 hasAuthorship W2151146130A5083726032 @default.
• W2151146130 hasConcept C126322002 @default.
• W2151146130 hasConcept C142724271 @default.
• W2151146130 hasConcept C168563851 @default.
• W2151146130 hasConcept C197934379 @default.
• W2151146130 hasConcept C204787440 @default.
• W2151146130 hasConcept C27081682 @default.
• W2151146130 hasConcept C2779134260 @default.
• W2151146130 hasConcept C2780479503 @default.
• W2151146130 hasConcept C44249647 @default.
• W2151146130 hasConcept C67774102 @default.
• W2151146130 hasConcept C71924100 @default.
• W2151146130 hasConcept C82789193 @default.
• W2151146130 hasConcept C90924648 @default.
• W2151146130 hasConcept C95190672 @default.
• W2151146130 hasConceptScore W2151146130C126322002 @default.
• W2151146130 hasConceptScore W2151146130C142724271 @default.
• W2151146130 hasConceptScore W2151146130C168563851 @default.
• W2151146130 hasConceptScore W2151146130C197934379 @default.
• W2151146130 hasConceptScore W2151146130C204787440 @default.
• W2151146130 hasConceptScore W2151146130C27081682 @default.
• W2151146130 hasConceptScore W2151146130C2779134260 @default.
• W2151146130 hasConceptScore W2151146130C2780479503 @default.
• W2151146130 hasConceptScore W2151146130C44249647 @default.
• W2151146130 hasConceptScore W2151146130C67774102 @default.
• W2151146130 hasConceptScore W2151146130C71924100 @default.
• W2151146130 hasConceptScore W2151146130C82789193 @default.
• W2151146130 hasConceptScore W2151146130C90924648 @default.
• W2151146130 hasConceptScore W2151146130C95190672 @default.
• W2151146130 hasIssue "5" @default.
• W2151146130 hasLocation W21511461301 @default.
• W2151146130 hasLocation W21511461302 @default.
• W2151146130 hasOpenAccess W2151146130 @default.
• W2151146130 hasPrimaryLocation W21511461301 @default.
• W2151146130 hasRelatedWork W1885119863 @default.
• W2151146130 hasRelatedWork W2062109784 @default.
• W2151146130 hasRelatedWork W2073750123 @default.
• W2151146130 hasRelatedWork W2114346778 @default.
• W2151146130 hasRelatedWork W2531052508 @default.
• W2151146130 hasRelatedWork W2592774827 @default.
• W2151146130 hasRelatedWork W2626084264 @default.
• W2151146130 hasRelatedWork W2976934717 @default.
• W2151146130 hasRelatedWork W4212933565 @default.

• next